JAK inhibitors in crohn's disease: ready to go?

Cecilia Dell'AvalleFerdinando D'AmicoRoberto GabbiadiniArianna Dal Buono Nicola PuglieseAlessandra ZilliFederica FurfaroGionata FiorinoMariangela AlloccaLaurent Peyrin-BirouletSilvio Danese

Published in: Expert opinion on investigational drugs (2022)

JAK-inhibitors are a promising class of oral compounds in moderate-severe CD. Further clinical trials are necessary in order to implement the available knowledge, especially on their long-term safety issues.

Keyphrases

clinical trial
healthcare
high intensity
early onset
randomized controlled trial
open label